Streetbeat News

Price Targets

OKTA

KeyBanc has maintained an Overweight rating on Okta's stock and raised its price target from $102 to $106. This has resulted in Okta's shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:35 pm

PACB

Piper Sandler analyst David Westenberg has maintained a Neutral rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $13 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:34 pm

NTRA

Piper Sandler analyst David Westenberg has maintained an Overweight rating on Natera (NASDAQ:NTRA) but lowered the price target from $80 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:33 pm

NEOG

Piper Sandler analyst David Westenberg has maintained a Neutral rating on Neogen (NASDAQ:NEOG) and lowered the price target from $24 to $17.5.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:31 pm

NEO

Piper Sandler analyst David Westenberg has maintained an Overweight rating on NeoGenomics (NASDAQ:NEO) but lowered the price target from $23 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:30 pm

CHKP

Morgan Stanley analyst Hamza Fodderwala has upgraded Check Point Software Technologies Ltd (CHKP) from Underweight to Equal-Weight and raised the price target from $118 to $144. The upgrade is due to stable demand, market share trends, and an expanding product portfolio. The analyst predicts a 3-4% topline growth in CY24/25 and an 8% EPS CAGR from CY23-25. CHKP shares are currently trading higher by 1.05% at $135.73.

Portfolio Pulse from Shivani Kumaresan

October 16, 2023 | 5:30 pm

JPM

Piper Sandler analyst Scott Siefers maintains an Overweight rating on JPMorgan Chase (NYSE:JPM) and raises the price target from $168 to $170.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:29 pm

ILMN

Piper Sandler analyst David Westenberg has maintained an Overweight rating on Illumina (NASDAQ:ILMN) but lowered the price target from $275 to $200.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:28 pm

HRMY

Piper Sandler analyst David Amsellem has maintained an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) but lowered the price target from $72 to $42.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:27 pm

FLGT

Piper Sandler analyst David Westenberg maintains a Neutral rating on Fulgent Genetics (NASDAQ:FLGT) and lowers the price target from $37 to $28.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 5:25 pm